4'-氟-[1,1'-联苯]-4-丙酸 | 893641-10-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4'-氟-[1,1'-联苯]-4-丙酸
• 英文名称: 3-(4-(4-fluorophenyl)phenyl)propanoic acid
• 英文别名: 3-(4'-fluorobiphenyl-4-yl)propanoic acid；[1,1'-Biphenyl]-4-propanoicacid, 4'-fluoro-；3-[4-(4-fluorophenyl)phenyl]propanoic acid
• CAS: 893641-10-6
• 化学式: C₁₅H₁₃FO₂
• 分子量: 244.265
• InChiKey: POPINLYDNNPCCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4'-氟-[1,1'-联苯]-4-丙酸 在 sodium hypochlorite 、 2,2,6,6-四甲基哌啶氧化物 、 碳酸氢钠 、 potassium bromide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.33h， 生成 3-(4'-fluorobiphenyl-4-yl)propanal
  参考文献：
  名称：

  WO2008/23336

  摘要：

  公开号：
• 作为产物：
  描述：

  3-(4-溴苯基)丙酸甲酯 在 四(三苯基膦)钯 、 水 、 碳酸氢钠 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 6.0h， 生成 4'-氟-[1,1'-联苯]-4-丙酸
  参考文献：
  名称：

  Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists

  摘要：

  Structure-affinity relationship (SAR) and structure-kinetics relationship (SKR) studies were combined to investigate a series of biphenyl anthranilic acid agonists for the HCA(2) receptor. In total, 27 compounds were synthesized and twelve of them showed higher affinity than nicotinic acid. Two compounds, 6g (IC50 = 75 nM) and 6z (IC50 = 108 nM) showed a longer residence time profile compared to nicotinic acid, exemplified by their kinetic rate index (KRI) values of 1.31 and 1.23, respectively. The SAR study resulted in the novel 2-F, 4-OH derivative (6x) with an IC50 value of 23 nM as the highest affinity HCA(2) agonist of the biphenyl series, although it showed a similar residence time as nicotinic acid. The SAR and SKR data suggest that an early compound selection based on binding kinetics is a promising addition to the lead optimization process. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.02.018

文献信息

• Synthesis, biological evaluation, and structure activity relationship (SAR) study of pyrrolidine amide derivatives as <i>N</i>-acylethanolamine acid amidase (NAAA) inhibitors
  作者：Pan Zhou、Lei Xiang、Dongsheng Zhao、Jie Ren、Yan Qiu、Yuhang Li

  DOI：10.1039/c8md00432c

  日期：——

  N-Acylethanolamine acid amidase (NAAA) is one of the key enzymes involved in the degradation of fatty acid ethanolamides (FAEs), especially for palmitoylethanolamide (PEA). Pharmacological blockage of NAAA restores PEA levels, providing therapeutic benefits in the management of inflammation and pain. In the current work, we showed the structure-activity relationship (SAR) studies for pyrrolidine amide

  N-酰基乙醇胺酸酰胺酶（NAAA）是参与脂肪酸乙醇酰胺（FAE）降解的关键酶之一，尤其是对于棕榈酰乙醇酰胺（PEA）而言。NAAA的药理学阻断作用可恢复PEA水平，从而在炎症和疼痛的治疗中提供治疗益处。在当前的工作中，我们显示了吡咯烷酰胺衍生物作为NAAA抑制剂的结构-活性关系（SAR）研究。检查了吡咯烷酰胺的末端苯基的一系列芳族取代基或取代基。SAR数据表明，较小的亲脂性3-苯基取代基对于最佳效用是优选的。构象柔性的接头增加了吡咯烷酰胺衍生物的抑制能力，但降低了其对脂肪酸酰胺水解酶（FAAH）的选择性。构象上受限的接头没有增强抑制剂对NAAA的效力，但是改善了对FAAH的选择性。开发了几种低微摩尔有效的NAAA抑制剂，其中包括带有刚性4-苯基肉桂酰基的4g。透析和动力学分析表明4g通过竞争和可逆的机制抑制NAAA。此外，4g在脂多糖（LPS）诱导的急性肺损伤（ALI）模型中显示出较高的抗
• MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Sattigeri Viswajanani J.

  公开号：US20100081610A1

  公开（公告）日：2010-04-01

  The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.

  本发明涉及β-羟基和氨基取代的羧酸，其作为基质金属蛋白酶抑制剂，尤其是对映异构体纯的β-羟基羧酸，以及合成该类化合物和含有本发明化合物的制药组合物的相关过程。本发明化合物在治疗各种炎症、自身免疫和过敏性疾病方面有用，例如治疗哮喘、类风湿性关节炎、慢性阻塞性肺疾病、鼻炎、骨关节炎、银屑病性关节炎、牛皮癣、肺纤维化、创伤愈合障碍、肺炎炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、新内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移以及其他以基质金属蛋白酶过度表达和过度活化为特征的炎症性疾病的方法中使用该化合物。
• Matrix metalloproteinase inhibitors
  申请人：Ranbaxy Laboratories Limited

  公开号：US08816073B2

  公开（公告）日：2014-08-26

  The present invention relates to β-hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for their synthesis, and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune, and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase.

  本发明涉及β-羟基和氨基取代的羧酸，其作为基质金属蛋白酶抑制剂，特别是对映异构体纯的β-羟基羧酸，以及其合成的相应过程和含有本发明化合物的制药组合物。本发明的化合物在治疗各种炎症、自身免疫和过敏性疾病方面有用，例如治疗哮喘、类风湿性关节炎、慢性阻塞性肺疾病、鼻炎、骨关节炎、银屑病性关节炎、牛皮癣、肺纤维化、创伤愈合障碍、肺部炎症、急性呼吸窘迫综合症、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、新内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移以及其他表现为基质金属蛋白酶过度表达和过度活化的炎症性疾病。
• PROCESS FOR PREPARING MATRIX METALLOPROTEINASE INHIBITORS AND CHIRAL AUXILIARY THEREFOR
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2074093B1

  公开（公告）日：2012-10-10
• US8507670B2
  申请人：——

  公开号：US8507670B2

  公开（公告）日：2013-08-13